The FDA approved orforglipron, a once-daily pill that works like Ozempic and Wegovy but doesn't require injections. The oral medication helps people lose 5-10% of their body weight and lowers blood sugar levels without fasting requirements.
Posts tagged as “new research”
Eli Lilly announced promising test results for its oral GLP-1 medication, adding to positive news about pill-form weight loss drugs. The company is working to develop alternatives to injectable medications that could reach more patients.
New research suggests the best strength training approach is choosing a resistance routine that fits your lifestyle and sticking with it consistently over time. The study indicates that simplicity and consistency may trump complex workout programs for most people.
A new study challenges concerns that popular weight-loss drugs like Ozempic and Wegovy cause significant muscle loss. Researchers found that much of the tissue loss previously attributed to muscle may actually come from healthier reductions in liver fat and other non-muscle tissue.
Previous research suggested that popular weight loss drugs like Wegovy and Zepbound caused people to lose too much muscle along with fat. A new study challenges this concern, finding that muscle mass loss may not be as severe as scientists initially thought.
New genetic research identified a specific gene variant that makes some people less responsive to GLP-1 weight loss drugs. People with this genetic variation may need different medications because their bodies don't process the GLP-1 hormone effectively.
A new review found that collagen supplements may provide real but modest health benefits, particularly for skin and joint health. The research suggests these supplements won't reverse aging dramatically but could offer some improvements.
A new study suggests GLP-1 medications may reduce levels of amyloid-beta and tau proteins linked to Alzheimer's disease. This potential brain-protective benefit could change how we think about these drugs beyond their weight loss effects.